NasdaqGM - Delayed Quote USD
ANI Pharmaceuticals, Inc. (ANIP)
58.72
+0.46
+(0.79%)
At close: May 30 at 4:00:02 PM EDT
58.72
-0.00
(-0.01%)
After hours: May 30 at 4:21:55 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.05 | 0.16 | 1.54 | 1.94 |
| Low Estimate | -0.25 | -0.06 | 1.12 | 1.3 |
| High Estimate | 0.19 | 0.43 | 2.15 | 2.66 |
| Year Ago EPS | -0.14 | -1.27 | -1.04 | 1.54 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 7 |
| Avg. Estimate | 187.18M | 192.78M | 788.19M | 846.34M |
| Low Estimate | 181.1M | 190M | 781.5M | 820.4M |
| High Estimate | 192.09M | 199.01M | 796.55M | 881.6M |
| Year Ago Sales | 138.04M | 148.33M | 614.38M | 788.19M |
| Sales Growth (year/est) | 35.60% | 29.97% | 28.29% | 7.38% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | 0.08 | -0 | 0.29 | -0.06 |
| EPS Actual | -0.14 | -1.27 | -0.55 | 0.69 |
| Difference | -0.22 | -1.27 | -0.84 | 0.75 |
| Surprise % | -282.60% | -38,038.14% | -287.50% | 1,161.54% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.05 | 0.16 | 1.54 | 1.94 |
| 7 Days Ago | 0.07 | 0.21 | 1.54 | 2.73 |
| 30 Days Ago | 0.27 | 0.27 | 1.05 | 2.83 |
| 60 Days Ago | 0.25 | 0.27 | 1 | 2.77 |
| 90 Days Ago | 0.41 | 0.48 | 1.93 | 3.58 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | 1 | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ANIP | 36.13% | 14.76% | 25.45% | 8.47% |
| S&P 500 | 13.08% | 2.49% | 7.56% | 13.96% |
Upgrades & Downgrades
| Reiterates | Guggenheim: Buy to Buy | 5/12/2025 |
| Maintains | Truist Securities: Hold to Hold | 4/21/2025 |
| Reiterates | Guggenheim: Buy to Buy | 4/11/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/17/2025 |
| Initiated | Jefferies: Buy | 3/14/2025 |
| Initiated | JP Morgan: Overweight | 3/12/2025 |
Related Tickers
EGRX Eagle Pharmaceuticals, Inc.
1.8000
+9.09%
AMPH Amphastar Pharmaceuticals, Inc.
25.71
+0.27%
NBIX Neurocrine Biosciences, Inc.
123.02
-0.52%
AMRX Amneal Pharmaceuticals, Inc.
7.32
+0.27%
IRWD Ironwood Pharmaceuticals, Inc.
0.5991
-5.13%
ASRT Assertio Holdings, Inc.
0.6643
-2.12%
PCRX Pacira BioSciences, Inc.
25.84
-0.35%
ANIK Anika Therapeutics, Inc.
11.15
-0.98%
INDV Indivior PLC
12.86
+3.63%
SIGA SIGA Technologies, Inc.
5.98
-2.92%